Makers Lab Peer Comparison

BSE: 506919

₹215.10

₹13.19 (6.53%)

As on 04-Nov-2026IST

Market cap

₹127 Cr

Revenue (TTM)

₹162 Cr

P/E Ratio

17

P/B Ratio

1.6

Div. Yield

0 %

Edit

	Makers Lab	Pfizer	Eris Lifesciences	CORONA Remedies	Strides Pharma
Market cap (₹ Cr)	127	17,532	16,891	14,676	9,328
Revenue (₹ Cr)	162	2,654	3,330	1,559	5,213
Net Profit (₹ Cr)	18.95	859.38	720.77	206.58	635.98
Net Margin (%)	11.50	30.42	21.60	13.15	11.92
RoE (%)	9.89	18.58	18.93	28.52	17.69
Price to Earnings	16.95	20.40	23.87	70.89	15.12
Price-To-Book	1.64	3.98	4.08	18.23	2.73

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Makers Lab	Pfizer	Eris Lifesciences	CORONA Remedies	Strides Pharma
Operating Revenue	162.40	2,654.29	3,329.63	1,559.11	5,213.26
Total Income	164.85	2,825.39	3,337.47	1,571.09	5,337.22
Total Expenditure	133.90	1,681.39	2,168.88	1,224.85	4,256.92
EBITDA	28.51	972.90	1,160.75	334.26	956.34
Depreciation	4.56	57.71	285.40	48.04	217.49
EBIT	23.95	915.19	875.35	286.22	738.85
Interest	0.67	8.91	187.51	8.48	172.06
Other Income	2.44	171.10	7.84	11.98	123.96
Exceptional Items	0.00	82.90	-53.14	-19.10	51.79
Profit before Tax	25.72	1,160.28	642.54	270.62	742.55
Provision for Tax	6.77	300.90	-78.23	64.04	106.56
Profit after Tax	18.95	859.38	720.77	206.58	635.98

Liabilities (₹ Cr)

	Makers Lab	Pfizer	Eris Lifesciences	CORONA Remedies	Strides Pharma
Shareholder's Funds	78.35	4,385.41	4,144.34	805.11	3,416.47
Minority Interest	-11.47	0.00	-10.85	0.00	-20.21
Non-Current Liabilities	8.93	222.21	758.48	108.63	883.34
Current Liabilities	37.88	685.36	2,681.14	333.00	3,134.98
Total Liabilities	166.62	4,921.88	7,246.72	--	6,806.56

Assets (₹ Cr)

	Makers Lab	Pfizer	Eris Lifesciences	CORONA Remedies	Strides Pharma
Non-Current Assets	72.33	905.21	5,578.78	720.43	3,199.94
Current Assets	102.88	4,024.56	1,800.86	473.68	4,037.16
Total Assets	166.62	4,921.88	7,246.72	--	6,806.56
Total Debt*	4.76	2.50	2,309.68	--	1,668.69
Net Current Assets	65.00	3,339.20	-880.28	140.68	902.19
Contingent Liabilities	4.71	370.49	51.57	--	118.51

Cashflow (₹ Cr)

	Makers Lab	Pfizer	Eris Lifesciences	CORONA Remedies	Strides Pharma
Cash From Operating Activities	14.29	967.57	537.99	--	702.52
Cash Flow from Investing Activities	-14.69	-561.67	-369.46	--	-173.04
Cash from Financing Activities	0.35	-798.31	-313.53	--	-453.41
Net Cash Inflow / Outflow	-0.05	-392.41	-145.00	--	76.07

Ratios

Profitability Ratios

	Makers Lab	Pfizer	Eris Lifesciences	CORONA Remedies	Strides Pharma
ROCE (%)	15.83	23.39	14.47	--	18.57
ROE (%)	9.89	18.58	18.93	28.52	17.69
ROA (%)	11.20	17.36	9.78	18.58	9.08
EBIT Margin (%)	14.74	34.48	26.29	18.36	14.17
Net Margin (%)	11.50	30.42	21.60	13.15	11.92
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Makers Lab	Pfizer	Eris Lifesciences	CORONA Remedies	Strides Pharma
Revenue Growth (%)	24.19	11.75	11.06	20.02	11.28
EBIT Growth (%)	358.28	21.45	13.71	22.30	8.34
Net Profit Growth (%)	387.90	2.39	60.98	18.28	55.25
EPS Growth (%)	30,791.92	13.17	80.38	26.44	32.65
Book Value Growth (%)	3.43	-0.34	36.71	--	21.78

Valuation Ratios

	Makers Lab	Pfizer	Eris Lifesciences	CORONA Remedies	Strides Pharma
Price / Earnings	16.96	21.98	22.11	66.31	16.16
Price / Book Value	1.64	3.98	4.08	18.23	2.73
Dividend Yield (%)	0.00	1.96	0.00	0.42	0.49
EV/EBITDA	4.19	14.83	16.48	44.20	11.28
Market Cap (₹ Cr)	79.77	21,592.90	17,980.08	--	8,643.60

Solvency Ratios

	Makers Lab	Pfizer	Eris Lifesciences	CORONA Remedies	Strides Pharma
Debt to Equity	0.00	0.00	0.10	0.00	0.17
Short term debt to equity ratio	0.04	0.00	0.12	--	0.33
Current Ratio	2.72	5.87	0.67	1.42	1.29
Quick Ratio	1.38	5.23	0.49	0.91	0.69
Interest Coverage	39.62	131.22	4.43	32.91	5.32

Operating Efficiency Ratios

	Makers Lab	Pfizer	Eris Lifesciences	CORONA Remedies	Strides Pharma
Debtors to sales (%)	13.46	9.10	18.98	10.94	28.08
Asset Turnover	0.96	0.54	0.45	1.40	0.74
Receivable days	62.18	26.06	63.88	--	64.34
Inventory Days	102.52	65.95	43.27	--	75.20
Payable days	90.08	81.01	151.85	--	218.23
Cash Conversion Cycle	74.62	11.00	-44.70	--	-78.69

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.